“the natural way to better health”  
LB17 Live Probiotics (Fermented food in Canada)
LB17 information
LB17 biomass
LB17 and lactic acid bacteria
LB17 beneficial effects
LB17 compared to other probiotics
LB17 bacteria functions
LB17 news
LB17 FAQ

Natural Nutritional Products
LB17 live Probiotics
Flax Hulls
100% Pure Antarctic Krill Oil
5-Mushroom Blend
GMC2 Liquid Glucosamine

Heavy Metal Test kits

Other Self Test
Free Radical Test
Water Test (2-test pack)
Adrenal Function (Koenigsburg) Test
Sulkowitch (calcium) Test
pH Test

Heavy Metals Detox

MF (metal free) Water

Eldon Blood Type Test

Practitioner Registration

Strategic Health Markers
Energy
pH Indicator
Free Radicals
Inflammation

 



New Therapies for Psoriasis

Laureen Neergaard
Associated Press - reported in C-Health News


November 4, 2003


It's a new era for patients covered in the itchy, scaly skin disease psoriasis. After years with few good treatments, doctors finally have a handful of therapies that promise to help control the incurable condition with fewer bad side effects.

What changed? Scientists learned that psoriasis isn't just a skin-deep disorder but a dysfunction of the immune system, so the new therapies target the real culprit (see below).

"Five to six years ago, I was telling my patients it was the wasteland," says Dr. Craig Leonardi of St. Louis University Medical School, who participated in studies of the new treatments. "Now there's this huge explosion of amazing drugs coming forward."

The new options don't help everyone, cautions Dr. Michael Tharp, dermatology chief at Chicago's Rush University Medical Center. And they're very expensive, costing $10,000 a year or more.

But, "it's a great first step," Tharp says. "Now we've got very directed molecules and know where they work and how they work. ... I hope it is just the beginning."

Two unique psoriasis shots, Amevive and Raptiva, recently won Food and Drug Administration approval. Two drugs already sold to treat other conditions -- Enbrel and Remicade -- are used against psoriasis, too. A list of other potential treatments is under study.

The four newest options haven't yet been compared to each other, but because each works somewhat differently, specialists expect hard-to-treat patients to find some relief among the bunch.

Some 4.5 million Americans have psoriasis. Of those, 1.5 million suffer moderate to severe symptoms -- their skin covered in red or white scaly patches that burn and itch. It's triggered when certain immune system cells, called memory effector T cells, run amok, causing skin cells to multiply faster than normal and become inflamed.

It can be life-altering.

"I wouldn't wear anything but long-legged pants and long-sleeved shirts because I got so tired of people asking me questions," says Lyle Newcomb, 60, of Milwaukie, Ore., who tried every treatment without success. "You don't allow yourself to get real close to anybody because you don't know how they're going to accept it."

Then Newcomb entered a study of Raptiva. "I had never been clear of psoriasis in my life, but I was totally clear in three weeks," and, two years later, weekly shots keep symptoms at bay.

Ointments and light therapy -- ultraviolet beams, sometimes with light-sensitizing drugs, a few times a week -- are effective for milder psoriasis.

Until now, severely hit patients had two powerful options, each with serious side effects. The immune suppressor cyclosporine, commonly used to prevent rejection of transplanted organs, can destroy kidneys. Inflammation-suppressing methotrexate, also used for cancer and rheumatoid arthritis, can cause liver damage.

The new biologically engineered treatments promise more targeted therapy without those risks:

--Amevive and Raptiva interfere with the harmful T cells, dramatically clearing psoriasis lesions in 20 percent to 40 percent of patients.

Amevive causes those T cells to die, explaining why some people's symptoms don't return for months after a three-month course of weekly shots. About 3,500 patients have begun Amevive since FDA approval in January, says maker Biogen Inc. The intramuscular shots are given in a doctor's office.

In contrast, Raptiva keeps harmful immune cells from getting into and inflaming skin, so patients must take it indefinitely. Sales will begin by Thanksgiving, say makers Genentech Inc. and Xoma Ltd. Patients give themselves weekly under-the-skin shots.

That difference means more than convenience; some insurance pays for in-office therapy but not at-home drugs.

--Instead of targeting T cells, Enbrel and Remicade inhibit a protein, TNF, that's crucial to inflammation. FDA-approved for certain types of arthritis, some doctors already use the drugs for psoriasis' skin lesions. The FDA now is evaluating Enbrel injections for that use; a final-stage study of intravenous Remicade is about to begin.

Specialists call the four new treatments largely safe but acknowledge that even mildly tinkering with the immune system for years might spur infections or cancer. "We're crossing our fingers," Tharp says.

That plus their huge cost means the new drugs are reserved for the worst patients. For less severe psoriasis sufferers, "we're back in the stone ages," Tharp says, urging companies to study better options for them, too.



Below is an image of a box of LB17 live probiotic and vegetable soft gel capsule
   
Each box contains 60 capsules


LB17 live probiotic biomass
LB17 is now also available in paste form without capsules for those who do not or cannot take capsules - see below

   
Above is a 50gm bottle of LB17 biomass. Next pic is image of the biomass in bulk paste form
> >


The above information is provided for general educational purposes only. It is not intended to replace competent health care advice received from a knowledgeable healthcare professional. You are urged to seek healthcare advice for the treatment of any illness or disease.
The Food Standards Agency (UK) has not evaluated these statements. This product is not intended to diagnose, treat, cure, or prevent any disease.



 Distributors - Nth America | Sth America | Asia | Europe | Africa | Oceania | Terms & Conditions | Private Policy |  CONTACT
Copyright 2001-2017 Osumex UK Ltd. All rights reserved.